Novo Nordisk information a number of lawsuits in the U.S. for trademark infringement and false promoting. Novo Nordisk filed a sequence of lawsuits throughout the nation final week, accusing a quantity of corporations, together with weight loss clinics and medical spas, of infringing its trademark rights and improperly selling its semaglutide merchandise Ozempic, Wegovy and Rybelsus. The pharmaceutical firm filed 9 lawsuits, alleging that the defendants abused its trademark rights by advertising and marketing semaglutide-based mixture weight loss medication with out approval from the U.S. Meals and Drug Administration. Practically half of the instances had been filed in Florida, and the firm additionally filed lawsuits in Tennessee, Montana, Colorado, Illinois and Texas.
Based in 1923, Novo Nordisk A/S is a Danish multinational pharmaceutical firm headquartered in Bagsværd with manufacturing amenities in 9 international locations and associates or places of work in 5 international locations and offers medical wants of individuals residing with a critical continual illness into progressive medicines and supply techniques.
Steve Benz is the Company Vice President Authorized and Basic Counsel since August 2022.
CEO: Lars Fruergaard Jørgensen
Subsidiaries: Dicerna Prescription drugs, Novo Nordisk Inc
Headquarters: Bagsværd, Denmark
Founders: Hans Christian Hagedorn, August Krogh
Printed by: www.lawyer-monthly.com